title: [Effectiveness and tolerance of depot leuprorelin acetate for preoperative endometrium flattening before endometrial ablation. German Leuprorelin Study Group].
abstract: OBJECTIVE
  In order to assess the efficacy and tolerability of leuprorelin acetate depot in pre-operative flattening of the endometrium prior to hysteroscopic endometrial ablation, 94 patients from eight centres were included in the per protocol analysis.
  
  
  METHODS
  The patients included were pre- or peri-menopausal, had completed their family planning and had intractable uterine bleeding. The primary target criterion was the reduction in maximum endometrial thickness after two injections of leuprorelin acetate depot with an interval of four weeks between injections. Surgery took place two weeks after the second injection.
  
  
  RESULTS
  Sufficient pre-treatment was achieved in 91.5% of the patients with > 50% decrease and/or a type 1 endometrium according to sonographic and/or endometrial atrophy (Score 11) according to the central histological evaluation. The endometrium was flattened by a mean of 4.0 +/- 4.1 mm. In terms of clinical response, amenorrhoea, hypomenorrhoea or normal menstruation were achieved after endometrial ablation. Hence 91.5% of patients benefited from the overall treatment after six weeks and still 83% after six months. The trial medication was well tolerated overall. The most common side-effect described was hot flushes which could be attributed to the deliberate oestrogen withdrawal.
  
  
  CONCLUSIONS
  In view of the good study results, hormone-suppressive pretreatment of the endometrium can be recommended prior to elective ablation. Surgery should take place during the oestrogen-suppressed phase.
authors.affiliation: Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universität Köln. Thomas.Roemer@medizin.uni-koeln.de
authors.forename: T
authors.initials: T
authors.lastname: Römer
authors.forename: R
authors.initials: R
authors.lastname: Deckardt
authors.forename: K
authors.initials: K
authors.lastname: Lobodasch
authors.forename: M
authors.initials: M
authors.lastname: Bernau
authors.forename: J
authors.initials: J
authors.lastname: Kemnitz
authors.forename: E
authors.initials: E
authors.lastname: Dewitt
authors.forename: E
authors.initials: E
authors.lastname: Koepcke
authors.forename: H C
authors.initials: HC
authors.lastname: Bethge
authors.forename: E
authors.initials: E
authors.lastname: Kienle
authors.forename: H
authors.initials: H
authors.lastname: Hillger
authors.forename: D
authors.initials: D
authors.lastname: Wallwiener
mesh_terms: D000328:Adult; D001706:Biopsy; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D004714:Endometrial Hyperplasia / Q000473:pathology / Q000601:surgery*; D004717:Endometrium / Q000187:drug effects / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D015907:Hysteroscopy; D016729:Leuprolide / Q000008:administration & dosage* / Q000009:adverse effects; D008595:Menorrhagia / Q000473:pathology / Q000601:surgery*; D008796:Metrorrhagia / Q000473:pathology / Q000601:surgery*; D008875:Middle Aged; D011300:Preoperative Care
chemical_list: D003692:Delayed-Action Preparations; D016729:Leuprolide